1990—2019年中国女性人群归因于代谢危险因素的乳腺癌疾病负担

doi:10.11904/j.issn.1002-3070.2023.02.003

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (2): 107-111.doi: 10.11904/j.issn.1002-3070.2023.02.003

1990—2019年中国女性人群归因于代谢危险因素的乳腺癌疾病负担

张馨¹, 吴羡美², 李虹¹, 刘晓舟¹, 孔德文¹, 陈琢³

1.哈尔滨医科大学附属肿瘤医院乳腺外科一病房(哈尔滨 150081);
2.哈尔滨医科大学附属肿瘤医院头颈鼻咽喉二病房;
3.哈尔滨医科大学附属肿瘤医院麻醉科

收稿日期:2023-02-12 修回日期:2023-04-06 出版日期:2023-04-28 发布日期:2023-05-30
通讯作者: 陈琢,E-mail:zhuochen930@hotmail.com
作者简介:张馨,女,(1984-),本科,主管护师,从事乳腺癌发病机制的研究。

The disease burden of breast cancer attributed to metabolic risk factors in the Chinese female population,from 1990 to 2019

ZHANG Xin¹, WU Xianmei², LI Hong¹, LIU Xiaozhou¹, KONG Dewen¹, CHEN Zhuo³

1. The First Ward of Breast Surgery,Harbin Medical University Cancer Hospital,Harbin 150081,China;
2. The Second Ward of Head,Neck,Nose and Throat,Harbin Medical University Cancer Hospital;
3. Department of Anesthesiology,Harbin Medical University Cancer Hospital

Received:2023-02-12 Revised:2023-04-06 Online:2023-04-28 Published:2023-05-30

摘要/Abstract

摘要： 目的分析1990—2019年中国女性人群归因于代谢危险因素乳腺癌疾病负担的变化趋势,为制定有针对性的防治策略提供科学依据。方法基于2019年全球疾病负担研究(Global burden of disease study 2019,GBD 2019)数据库,采用死亡、伤残调整生命年(Disability adjusted life year,DALY)、伤残损失健康寿命年(Years lived with disability,YLD)、早死损失寿命年(Years of life lost,YLL)和人群归因分值(Population attributable faction,PAF),分析中国女性人群归因于代谢危险因素的乳腺癌疾病负担变化趋势。结果 1990—2019年,中国与全球归因代谢危险因素乳腺癌的年龄标化死亡率和DALY率均呈上升趋势,中国归因标化死亡率和DALY率平均每年分别上升1.79%(95% CI:1.51%~2.07%,P＜0.05)和1.77%(95% CI:1.45%~2.09%,P＜0.05),全球归因标化死亡率和DALY率平均每年分别上升0.80%(95% CI:0.69%~0.92%,P＜0.05)和0.97%(95% CI:0.91%~1.04%,P＜0.05),中国上升幅度高于全球。1990—2019年中国女性各年龄组归因代谢危险因素乳腺癌所致的PAF存在差异,50~69以及70岁以上年龄组PAF值较大;归因DALY率在50~69年龄组达最高,归因死亡率随年龄的增长呈上升趋势,在≥70岁年龄组达最高。与1990年相比,2019年代谢危险因素中高体重指数所致乳腺癌的死亡人数以及DALY分别增长了450.34%和440.28%,死亡率以及DALY率分别增长了352.48%和344.20%。结论中国女性人群归因于代谢危险因素乳腺癌疾病负担沉重,中老年女性人群为高危人群。此外,代谢危险因素中高体重指数是重要危险因素。

关键词: 中国, 乳腺癌, 代谢危险因素, 疾病负担

Abstract: Objective The Objective of this study was to analyze the changing trend of breast cancer disease burden attributable to metabolic risk factors in Chinese female population between 1990 and 2019,so as to provide scientific basis for formulating targeted prevention and control strategies. Methods Based on the global burden of disease study 2019(GBD 2019)database,mortality,disability adjusted life year(DALY),disability adjusted life year(DALY),years lived with disability(YLD),years of life lost(YLL),and population attributable fraction(PAF)were calculated to analyze the changing trend of breast cancer disease burden attributed to metabolic risk factors in Chinese female population. Results The age-standardized mortality and the DALY rate of breast cancer attributable to metabolic risk factors in China and the World both showed an upward trend between 1990 and 2019.The attributable age-standardized mortality and DALY rate in China increased by 1.79%(95% CI:1.51%-2.07%,P＜0.05)and 1.77%(95% CI:1.45%-2.09%,P＜0.05),the global attributable standardized mortality and DALY rate increased by 0.80%(95% CI:0.69%-0.92%,P＜0.05)and 0.97%(95% CI:0.91%-1.04%,P＜0.05),respectively,and the increase in China was higher than that in the World.There were differences in the PAF attributable to metabolic risk factors of breast cancer among Chinese women in different age groups between 1990 and 2019,and the PAF value was higher in the age group of 50-69 and over 70 years old.The attributable DALY rate was the highest in the age group of 50-69,and the attributable mortality increased with age,reaching the highest in the ≥70-year-old age group.Compared with 1990,the number of breast cancer deaths and DALY caused by high body mass index among metabolic risk factors in 2019 increased by 450.34% and 440.28%,respectively,and the mortality and DALY rate increased by 352.48% and 344.20%,respectively. Conclusion The burden of breast cancer in Chinese female population is heavy due to metabolic risk factors,and middle-aged and elderly female population is a high-risk group.In addition,high body mass index is an important risk factor among metabolic risk factors.

Key words: China, Breast cancer, Metabolic risk factors, Burden of disease

中图分类号:

R737.9

张馨, 吴羡美, 李虹, 刘晓舟, 孔德文, 陈琢. 1990—2019年中国女性人群归因于代谢危险因素的乳腺癌疾病负担[J]. 实用肿瘤学杂志, 2023, 37(2): 107-111.

ZHANG Xin, WU Xianmei, LI Hong, LIU Xiaozhou, KONG Dewen, CHEN Zhuo. The disease burden of breast cancer attributed to metabolic risk factors in the Chinese female population,from 1990 to 2019[J]. Journal of Practical Oncology, 2023, 37(2): 107-111.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.02.003

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I2/107

参考文献

1 Sharma R.Global,regional,national burden of breast cancer in 185 countries:evidence from GLOBOCAN 2018[J].Breast Cancer Res Treat,187(2):557-567.
2 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249.
3 张雅聪,吕章艳,宋方方,等.全球及我国乳腺癌发病和死亡变化趋势[J].肿瘤综合治疗电子杂志,2021,7(2):14-20.
4 赫捷,陈万青,李霓,等.中国女性乳腺癌筛查与早诊早治指南(2021,北京)[J].中国肿瘤,2021,30(3):161-191.
5 刘宗超,李哲轩,张阳,等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2021,7(2):1-14.
6 郑世海,徐冠英.德州市城区≥50岁的女性健康现状的调查分析[J].中国社区医师,2018,34(17):176-177.
7 GBD 2019 Diseases and Injuries Collaborators.Global burden of 369 diseases and injuries in 204 countries and territories,1990—2019:a systematic analysis for the Global Burden of Disease Study 2019[J].Lancet,2020,396(10258):1204-1222.
8 GBD 2019 Risk Factors Collaborators.Global burden of 87 risk factors in 204 countries and territories,1990—2019:a systematic analysis for the Global Burden of Disease Study 2019[J].Lancet,2020,396(10258):1223-1249.
9 GBD 2019 Demographics Collaborators.Global age-sex-specific fertility,mortality,healthy life expectancy(HALE),and population estimates in 204 countries and territories,1950-2019:a comprehensive demographic analysis for the Global Burden of Disease Study 2019[J].Lancet,2020,396(10258):1160-1203.
10 李茜瑶,周莹,黄辉,等.疾病负担研究进展[J].中国公共卫生,2018,34(5):777-780.
11 陈静静,田学斌.1990—2019年全球HIV/AIDS疾病负担及归因危险因素分析[J].现代预防医学,2023,50(6):993-1002.
12 Kim HJ,Fay MP,Feuer EJ,et al.Permutation tests forjoinpoint regression with applications to cancer rates[J].Stat Med,2001,20(4):655.
13 张蒙,崔永春,王春平,等.1990—2019年中国女性乳腺癌疾病负担及其危险因素变化趋势分析[J].中华肿瘤防治杂志,2022,29(7):456-462.
14 张雪,董晓平,管雅喆,等.女性乳腺癌流行病学趋势及危险因素研究进展[J].肿瘤防治研究,2021,48(1):87-92.
15 Hair BY,Xu Z,Kirk EL,et al.Body mass index associated with genome-wide methylation in breast tissue[J].Breast Cancer Res Treat,2015,151(2):453-463.
16 Reaves DK,Ginsburg E,Bang JJ,et al.Persistent organic pollutants and obesity:are they potential mechanisms for breast cancer promotion[J].Endocr Relat Cancer,2015,22(2):69.
17 汤志英,万芳.乳腺癌发病流行病学影响因素调查及疗效分析[J].中国妇幼保健,2021,36(10):2349-2353.
18 蒲星月,马原,钟志刚.2006—2020年中国女性乳腺癌死亡趋势分析—基于年龄-时期-出生队列模型[J].卫生经济研究,2023,40(2):28-33.
19 王昭君,马海广,胡晓清,等.体质指数和绝经后乳腺癌患者临床病理因素的关系[J].中国妇幼保健,2022,37(12):2144-2147.
20 李琦,高玉堂,刘大可,等.上海市不同出生队列妇女月经生育等因素变化趋势分析[J].肿瘤,2004,24(6):530-533.
21 朱雅玲,张彬.人口结构变动下中国消费的未来趋势——基于第七次全国人口普查数据的分析[J].陕西师范大学学报(哲学社会科学版),2021,50(4):149-162.
22 Avgerinos KI,Spyrou N,Mantzoros CS,et al.Obesity and cancer risk:Emerging biological mechanisms and perspectives[J].Metabolism,2019,92:121-135.
23 Jeong SH,An Y,Ahn C,et al.Body mass index and risk of breast cancer molecular subtypes in Korean women:a case–control study[J].Breast Cancer Res Treat,2020,179(2):459-470.
24 陈飞,王悠清.1990—2019年中国食管癌疾病负担及其变化趋势分析[J].中国肿瘤,2021,30(6):401-407.

[1]	刘欣欣, 马西元, 缪美琪, 王语晴, 陈晶. IL-6及其受体在乳腺癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 149-154.
[2]	冯诚天, 黄芙蓉, 姜永冬. 脂质代谢与乳腺癌曲妥珠单抗耐药性机制的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 155-159.
[3]	文世超, 王静萱. 铜依赖性细胞死亡及铜在乳腺癌治疗中的研究现状[J]. 实用肿瘤学杂志, 2023, 37(2): 185-189.
[4]	周孟孟, 徐文超, 俞浩. 1990—2019年江苏省男性前列腺癌疾病负担分析[J]. 实用肿瘤学杂志, 2023, 37(1): 1-5.
[5]	余银平, 蔺嘉楠, 王立中, 蒋威华. 癌源性外泌体对乳腺癌MCF-7细胞生物学行为的影响[J]. 实用肿瘤学杂志, 2023, 37(1): 26-31.
[6]	教冲, 史雨鑫, 徐浩译, 马斌林, 董朝. 二甲双胍对不同亚型乳腺癌伴2型糖尿病患者预后影响的研究[J]. 实用肿瘤学杂志, 2022, 36(6): 531-537.
[7]	吴蕊玥, 朱凯丽, 杨景茹, 令晓玲. HER2低表达乳腺癌的临床研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 570-575.
[8]	王星涵, 吕雅蕾. 曲妥珠单抗耐药机制及HER2阳性乳腺癌耐药后的治疗策略[J]. 实用肿瘤学杂志, 2022, 36(5): 445-451.
[9]	康子曼, 杨聃琳, 孙建男. 乳腺MRI图像纹理分析在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 472-476.
[10]	李智慧, 李志高. 恩美曲妥珠单抗T-DM1在HER2阳性乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 477-482.
[11]	陈嘉一, 白彦灵. 乳腺癌患者体重指数及体位固定方式对保乳术后调强放射治疗摆位误差的影响[J]. 实用肿瘤学杂志, 2022, 36(4): 327-331.
[12]	赵丹妮, 闫石, 蔡莉. 乳腺癌随访和药物副作用管理策略的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 369-373.
[13]	宗禹萱, 庞达. 热休克蛋白90在乳腺癌发生发展及治疗中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 381-385.
[14]	杨子涵, 许守平, 庞达. 乳腺癌发生腋窝外三角组织转移特点与影响因素分析[J]. 实用肿瘤学杂志, 2022, 36(3): 226-232.
[15]	何伟丹, 李志高. FSIP1促进乳腺癌细胞迁移和侵袭并导致患者不良预后[J]. 实用肿瘤学杂志, 2022, 36(3): 233-238.

1990—2019年中国女性人群归因于代谢危险因素的乳腺癌疾病负担

The disease burden of breast cancer attributed to metabolic risk factors in the Chinese female population,from 1990 to 2019

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价